The US Food and Drug Administration is considering policies to ensure communications about biosimilars and interchangeable biosimilars do not scare patients away from using the products, an agency official said on 4 December.
While the FDA has been focused on proactively communicating information about the safety and efficacy of biosimilars, it also is looking to take steps to limit misinformation about such products,...